Last reviewed · How we verify
PDLLA
At a glance
| Generic name | PDLLA |
|---|---|
| Sponsor | Jin Cheol Kim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions (NA)
- Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction (NA)
- Treatment of Adipose Tissue and Skin Laxity at the Buttocks by PDLLA, US and RF
- Thin Versus Thicker Strut Thickness Stents in Primary Percutaneous Intervention (NA)
- A Prospective, Split-face, Randomized Study of the Poly-D, L Lactic Acid (PDLLA) for Photoaged Skin (NA)
- To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PDLLA CI brief — competitive landscape report
- PDLLA updates RSS · CI watch RSS
- Jin Cheol Kim portfolio CI